Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Co-Administration of Thyroid Hormone Receptor-beta Agonist ALG-055009 and Incretin Receptor Agonists Leads to Synergistic Weight Loss and Modulation of Molecular Pathways Underlying Adipocyte Dysfunction in Diet-Induced Obese Mice

Wednesday, May 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study discusses the co-administration of the thyroid hormone receptor-beta agonist ALG-055009 with incretin receptor agonists, demonstrating a synergistic effect on weight loss in diet-induced obese mice. This combination also modulates molecular pathways linked to adipocyte dysfunction, suggesting a promising avenue for obesity treatment. The findings contribute to understanding obesity management strategies.
Price reaction · baseline $6.47 (2026-05-12 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close · peak
+3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Synergistic weight loss observed with co-administration.
  • Modulation of molecular pathways shows potential for obesity treatment.
  • Research highlights innovative approaches to adipocyte dysfunction.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-055009?

ALG-055009 is a thyroid hormone receptor-beta agonist studied for its effects on weight loss.

How does ALG-055009 affect weight loss?

It shows synergistic weight loss when co-administered with incretin receptor agonists.

What pathways does ALG-055009 modulate?

It modulates molecular pathways related to adipocyte dysfunction.

What type of mice were used in the study?

The research was conducted on diet-induced obese mice.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-055009 weight loss incretin receptor agonists thyroid hormone adipocyte dysfunction
Last updated: May 13, 2026

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →